Alnylam Pharma(CH:DUL)
CHF 138.580.00 (0.00%)
CH:DUL
Alnylam Pharma stock forecast
CHF 138.58
At close:0.00 (0.00%)
Alnylam Pharma (DUL) Stock Forecast & Price Target
0 Followers
DUL Analyst Ratings
Moderate Buy
18Buy8Hold0Sell
Based on 26 analysts giving stock ratings to Alnylam Pharma in the past 3 months
DUL Stock 12 Month Forecast
Average Price Target
CHF 254.54▲(83.68% Upside)Based on 26 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is CHF 254.54 with a high forecast of CHF 372.93 and a low forecast of CHF 163.11. The average price target represents a 83.68% change from the last price of CHF 138.58.
Past 12 Months12 Month ForecastJan2026Oct2026
HighCHF 372.93
AverageCHF 254.54
LowCHF 163.11
Highest Price TargetHighestCHF 372.93Average Price TargetCHF 254.54Lowest Price TargetLowestCHF 163.11
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Eric Joseph | Citi | CHF 262.28→CHF 204.91 | buy | 47.86%Upside | Reiterated | 11/10/26 | ||
| Edward Tenthoff | Piper Sandler | CHF 336.05 | buy | 142.50%Upside | Reiterated | 11/10/26 | ||
| Patrick Trucchio | H.C. Wainwright | CHF 397.52→CHF 372.93 | buy | 169.11%Upside | Reiterated | 11/06/26 | ||
| Olivia Brayer | Cantor Fitzgerald | CHF 266.38→CHF 237.69 | hold | 71.52%Upside | Reiterated | 11/06/26 | ||
| David Lebowitz | BMO Capital | CHF 237.69→CHF 239.33 | buy | 72.70%Upside | Assigned | 11/05/26 | ||
| Kostas Biliouris | Oppenheimer | CHF 262.28 | buy | 89.26%Upside | Reiterated | 11/05/26 | ||
| Tazeen Ahmad | Bank of America Securities | ― | buy | ― | Reiterated | 11/05/26 | ||
| Derek Archila | Wells Fargo | CHF 180.32 | hold | 30.12%Upside | Reiterated | 11/04/26 | ||
| Eliana Merle | Barclays | CHF 368.83→CHF 311.46 | buy | 124.75%Upside | Reiterated | 11/02/26 | ||
| Danielle Brill | Truist Financial | CHF 258.18→CHF 184.42 | hold | 33.08%Upside | Downgraded | 11/02/26 | ||
| Whitney Ijem | Canaccord Genuity | CHF 351.62→CHF 264.74 | buy | 91.04%Upside | Reiterated | 11/02/26 | ||
| Keay Nakae | Chardan Capital | CHF 348.34→CHF 307.36 | buy | 121.79%Upside | Reiterated | 10/30/26 | ||
| Martin Auster | Raymond James | CHF 344.24→CHF 258.18 | buy | 86.31%Upside | Reiterated | 10/30/26 | ||
| Joon Lee | UBS | CHF 290.15→CHF 269.66 | buy | 94.59%Upside | Reiterated | 10/30/26 | ||
| Jeffrey Walch | Bernstein | CHF 163.11 | hold | 17.70%Upside | Downgraded | 10/30/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Eric JosephCiti | BuyReiteratedCHF 262.28→CHF 204.91 | 11/10/26 | 47.86%Upside | ||
| Edward TenthoffPiper Sandler | BuyReiteratedCHF 336.05 | 11/10/26 | 142.50%Upside | ||
| Patrick TrucchioH.C. Wainwright | BuyReiteratedCHF 397.52→CHF 372.93 | 11/06/26 | 169.11%Upside | ||
| Olivia BrayerCantor Fitzgerald | HoldReiteratedCHF 266.38→CHF 237.69 | 11/06/26 | 71.52%Upside | ||
| David LebowitzBMO Capital | BuyAssignedCHF 237.69→CHF 239.33 | 11/05/26 | 72.70%Upside | ||
| Kostas BiliourisOppenheimer | BuyReiteratedCHF 262.28 | 11/05/26 | 89.26%Upside | ||
| Tazeen AhmadBank of America Securities | BuyReiterated | 11/05/26 | ― | ||
| Derek ArchilaWells Fargo | HoldReiteratedCHF 180.32 | 11/04/26 | 30.12%Upside | ||
| Eliana MerleBarclays | BuyReiteratedCHF 368.83→CHF 311.46 | 11/02/26 | 124.75%Upside | ||
| Danielle BrillTruist Financial | HoldDowngradedCHF 258.18→CHF 184.42 | 11/02/26 | 33.08%Upside | ||
| Whitney IjemCanaccord Genuity | BuyReiteratedCHF 351.62→CHF 264.74 | 11/02/26 | 91.04%Upside | ||
| Keay NakaeChardan Capital | BuyReiteratedCHF 348.34→CHF 307.36 | 10/30/26 | 121.79%Upside | ||
| Martin AusterRaymond James | BuyReiteratedCHF 344.24→CHF 258.18 | 10/30/26 | 86.31%Upside | ||
| Joon LeeUBS | BuyReiteratedCHF 290.15→CHF 269.66 | 10/30/26 | 94.59%Upside | ||
| Jeffrey WalchBernstein | HoldDowngradedCHF 163.11 | 10/30/26 | 17.70%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Alnylam Pharma
3 Months
Success Rate24/40 ratings generated profit
60%
Average Return
+5.20%
Copying Keay Nakae's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.20% per trade.
1 Year
Success Rate26/40 ratings generated profit
65%
Average Return
+16.24%
Copying Keay Nakae's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +16.24% per trade.
2 Years
Success Rate27/40 ratings generated profit
68%
Average Return
+26.78%
Copying Keay Nakae's trades and holding each position for 2 Years would result in 67.50% of your transactions generating a profit, with an average return of +26.78% per trade.
DUL Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 34 | 35 | 29 | 27 | 27 |
| Buy | 19 | 23 | 24 | 20 | 11 |
| Hold | 10 | 9 | 9 | 14 | 15 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 63 | 67 | 62 | 61 | 53 |
In the current month, DUL has received 38 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. DUL average Analyst price target in the past 3 months is 254.54.
DUL Financial Forecast
HighCHF 2.15
ConsensusCHF 1.42
LowCHF 0.48
DUL Earnings Forecast
Next quarter’s earnings estimate for DUL is CHF 1.42 with a range of CHF 0.48 to CHF 2.15. The previous quarter’s EPS was CHF 12.98. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF 1.34B
ConsensusCHF 1.26B
LowCHF 1.2B
DUL Sales Forecast
Next quarter’s sales forecast for DUL is CHF 1.26B with a range of CHF 1.20B to CHF 1.34B. The previous quarter’s sales results were CHF 1.20B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
DUL Stock Forecast FAQ
What is CH:DUL’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharma’s 12-month average price target is CHF254.54.
What is CH:DUL’s upside potential, based on the analysts’ average price target?
Alnylam Pharma has 83.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Alnylam Pharma a Buy, Sell or Hold?
Alnylam Pharma has a consensus rating of Moderate Buy, which is based on 18 buy ratings, 8 hold ratings and 0 sell ratings.
What is Alnylam Pharma’s share price target?
The average share price target for Alnylam Pharma is CHF254.54. This is based on 26 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF372.93, and the lowest forecast is CHF163.11. The average share price target represents a 83.68% increase from the current price of CHF138.579.
What do analysts say about Alnylam Pharma?
Alnylam Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Street analysts.
How can I buy shares of Alnylam Pharma?
To buy shares of CH:DUL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
